How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,603 results for

Breast MRI

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. ACR–ASNR Practice Parameter for the Performance of Non-Breast Magnetic Resonance Imaging (MRI) Guided Procedures

ACR–ASNR Practice Parameter for the Performance of Non-Breast Magnetic Resonance Imaging (MRI) Guided Procedures PRACTICE PARAMETER MRI Guided / 1 The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study (...) in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized. Revised 2013 (Resolution 8)* ACR–ASNR PRACTICE PARAMETER FOR THE PERFORMANCE OF NON- BREAST MAGNETIC RESONANCE IMAGING (MRI) GUIDED PROCEDURES PREAMBLE This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards

2019 American Society of Neuroradiology

2. MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer

MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer MRI performance in detecting pathologic complete response (pCR) post-neoadjuvant chemotherapy (NAC) in breast cancer has been previously explored. However, since tumor response varies by molecular subtype, it is plausible that imaging performance also varies. Therefore, we performed a literature review on subtype-specific MRI performance in detecting pCR post-NAC.Two reviewers searched Cochrane (...) , PubMed, and EMBASE for articles published between 2013 and 2018 that examined MRI performance in detecting pCR post-NAC. After filtering, ten primary research articles were included. Statistical metrics, such as sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were extracted per study for triple negative, HR+/HER2-, and HER2+ patients.Ten studies involving 2310 patients were included. In triple negative breast cancer, MRI showed NPV (58-100%) and PPV

2019 EvidenceUpdates

3. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI (PubMed)

The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI To compare breast density measured on digital breast tomosynthesis (DBT) (BI-RADS-based breast composition and fully-automatic estimation) and magnetic resonance imaging (MRI) (BI-RADS amount of fibroglandular tissue), and to evaluate the diagnostic performance in terms of sensitivity and specificity of DBT and MRI (...) in a predominantly dense breast population.Between 2015 and 2016, 152 women with 103 breast malignancies, who underwent 3-T breast MRI and DBT within 2 months' time, were enrolled in this study. Breast composition/fibroglandular tissue and findings on DBT (two readers) and MRI were reported using BI-RADS 5th edition. Digital mammography images were analysed for breast percent density (PD) using the Libra software tool.A majority of women had dense breasts as categorised by breast composition c (heterogeneously

Full Text available with Trip Pro

2018 European radiology

4. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers. (PubMed)

The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers. Higher background parenchymal enhancement (BPE) could be used for stratification of MRI screening programs since it might be related to a higher breast cancer risk. Therefore, the purpose of this study is to correlate BPE to patient and tumor characteristics in women with unilateral MRI-screen detected breast cancer who participated (...) in an intermediate and high risk screening program. As BPE in the affected breast may be difficult to discern from enhancing cancer, we assumed that BPE in the contralateral breast is a representative measure for BPE in women with unilateral breast cancer.This retrospective study was approved by our local institutional board and a waiver for consent was granted. MR-examinations of women with unilateral breast cancers screen-detected on breast MRI were evaluated by two readers. BPE in the contralateral breast

Full Text available with Trip Pro

2018 PLoS ONE

5. Clinical value of delayed 18F-FDG PET/CT for predicting nipple-areolar complex involvement in breast cancer: A comparison with clinical symptoms and breast MRI. (PubMed)

Clinical value of delayed 18F-FDG PET/CT for predicting nipple-areolar complex involvement in breast cancer: A comparison with clinical symptoms and breast MRI. We aimed to evaluate the predictive value of delayed 18F-FDG PET/CT for identifying malignancies involved in the nipple-areolar complex (NAC) in comparison with clinical symptoms and breast MRI.We enrolled 90 patients who underwent preoperative delayed 18F-FDG PET/CT and MRI between October 2015 and May 2017. We calculated the NAC (...) -Standardized uptake value ratio (SUVR) using the following formula: maximum SUV (SUVmax) of the NAC in the malignant breast /SUVmax of the NAC in the contralateral normal breast on early (NAC-SUVRearly) and delayed (NAC-SUVRdelay) phase images. MRI was used to measure the distance between the tumor and NAC and to analyze NAC enhancement patterns. Univariate and multivariate analyses were performed to identify significant predictive factors for NAC involvement.Seventeen patients were confirmed to have

Full Text available with Trip Pro

2018 PLoS ONE

6. Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications. (PubMed)

Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications. Background Screening breast MRI is recommended for women with BRCA mutation or a history of chest radiation, but guidelines are equivocal for MRI screening of women with a personal history of breast cancer or high-risk lesion. Purpose To evaluate screening breast MRI performance across women with different elevated breast cancer risk indications. Materials and Methods All screening breast (...) MRI examinations performed between 2011 and 2014 underwent retrospective medical record review. Indications for screening were as follows: BRCA mutation carrier or history of chest radiation (BRCA/RT group), family history of breast cancer (FH group), personal history of breast cancer (PH group), and history of high-risk lesion (HRL group). Screening performance metrics were calculated and compared among indications by using logistic regression adjusted for age, available prior MRI, mammographic

2019 Radiology

7. The Association of Background Parenchymal Enhancement at Breast MRI with Breast Cancer: A Systematic Review and Meta-Analysis. (PubMed)

The Association of Background Parenchymal Enhancement at Breast MRI with Breast Cancer: A Systematic Review and Meta-Analysis. Background The higher level of background parenchymal enhancement (BPE) at breast MRI has the potential for early detection and prediction of the risk of breast cancer. However, conflicting findings have been reported about the association between the level of BPE at breast MRI and the presence of breast cancer. Purpose To evaluate the association between qualitative (...) and quantitative BPE at dynamic contrast material-enhanced MRI and breast cancer among populations with average risk and high risk separately. Materials and Methods A retrospective meta-analysis of observational studies comparing either qualitative or quantitative assessments of BPE in women with and women without breast cancer was performed for studies published through July 2018. Pooled odds ratios (ORs) or standardized mean differences and 95% confidence intervals (CIs) were estimated by using DerSimonian

2019 Radiology

8. Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer. (PubMed)

Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer. Background There is lack of consensus regarding the use of breast MRI for routine surveillance for second breast cancer events in women with a personal history of breast cancer. Purpose To compare performance of surveillance mammography with breast MRI. Materials and Methods This observational cohort study used prospectively collected data and included 13 266 women age 18 years and older (mean (...) age, 60 years ± 13) with stage 0-III breast cancer who underwent 33 938 mammographic examinations and 2506 breast MRI examinations from 2005 to 2012 in the Breast Cancer Surveillance Consortium. Women were categorized into two groups: mammography alone (n = 11 745) or breast MRI (n = 1521). Performance measures were calculated by using end-of-day assessment and occurrence of second breast cancer events within 1 year of imaging. Logistic regression was used to compare performance for breast MRI

2019 Radiology

9. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer. (PubMed)

Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer. Background In patients who are expected to achieve axillary pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC), omission of axillary lymph node (LN) dissection could prevent morbidity and complications. Purpose To develop a clinical model to predict residual axillary LN metastasis in patients with clinically node-positive breast cancer after NAC by using (...) MRI and US. Materials and Methods In this retrospective study, women with clinically node-positive breast cancer who were treated with NAC following surgery between January 2015 and September 2017 were included. The patients were randomly assigned to a test and validation set (7:3 ratio). Univariable and multivariable logistic regression analyses were performed to evaluate the independent predictors of residual axillary LN metastasis in the test set. A prediction risk score was developed based

2019 Radiology

10. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer: MRI and Pathologic Complete Response. (PubMed)

MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer: MRI and Pathologic Complete Response. In the setting where determining extent of residual disease is key for surgical planning after neoadjuvant chemotherapy (NAC), we evaluate the reliability of MRI in predicting pathologic complete response (pCR) of the breast primary and axillary nodes after NAC.Patients who had MRI before and after NAC between June 2014 and August (...) 2015 were identified in a prospective database after IRB approval. Post-NAC MRI of the breast and axillary nodes was correlated with residual disease on final pathology. Pathologic complete response was defined as absence of invasive and in situ disease.We analyzed 129 breast cancers. Median patient age was 50.8 years (range 27.2 to 80.6 years). Tumors were human epidermal growth factor receptor 2 amplified in 52 of 129 (40%), estrogen receptor-positive/human epidermal growth factor receptor 2

Full Text available with Trip Pro

2017 Journal of the American College of Surgeons

11. Magnetic resonance imaging (MRI) for surveillance for breast cancer recurrence following mastectomy and breast reconstruction

Magnetic resonance imaging (MRI) for surveillance for breast cancer recurrence following mastectomy and breast reconstruction Magnetic resonance imaging (MRI) for surveillance for breast cancer recurrence following mastectomy and breast reconstruction Magnetic resonance imaging (MRI) for surveillance for breast cancer recurrence following mastectomy and breast reconstruction Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Magnetic resonance imaging (MRI) for surveillance for breast cancer recurrence following mastectomy and breast reconstruction. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions In the United States, an estimated 235,030 new cases of invasive breast cancer will be diagnosed in 2014, and an estimated 40,430 patients will die of the disease. Given a choice of breast-conserving surgery plus adjunct radiotherapy

2014 Health Technology Assessment (HTA) Database.

12. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis (PubMed)

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis Radiomics is an emerging technology for imaging biomarker discovery and disease-specific personalized treatment management. This paper aims to determine the benefit of using multi-modality radiomics data from PET and MR images in the characterization breast cancer phenotype and prognosis. Eighty-four features were extracted from PET and MR images of 113 breast cancer patients. Unsupervised (...) clustering based on PET and MRI radiomic features created three subgroups. These derived subgroups were statistically significantly associated with tumor grade (p = 2.0 × 10-6), tumor overall stage (p = 0.037), breast cancer subtypes (p = 0.0085), and disease recurrence status (p = 0.0053). The PET-derived first-order statistics and gray level co-occurrence matrix (GLCM) textural features were discriminative of breast cancer tumor grade, which was confirmed by the results of L2-regularization logistic

Full Text available with Trip Pro

2018 NPJ breast cancer

13. TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer (TMEM-MRI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03694756

2018 Clinical Trials

14. Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRI (PubMed)

Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRI Radiomics deals with the high throughput extraction of quantitative textural information from radiological images that not visually perceivable by radiologists. However, the biological correlation between radiomic features and different tissues of interest has not been established. To that end, we present the radiomic feature mapping framework to generate radiomic MRI (...) texture image representations called the radiomic feature maps (RFM) and correlate the RFMs with quantitative texture values, breast tissue biology using quantitative MRI and classify benign from malignant tumors. We tested our radiomic feature mapping framework on a retrospective cohort of 124 patients (26 benign and 98 malignant) who underwent multiparametric breast MR imaging at 3 T. The MRI parameters used were T1-weighted imaging, T2-weighted imaging, dynamic contrast enhanced MRI (DCE-MRI

Full Text available with Trip Pro

2017 NPJ breast cancer

15. Concurrent versus Sequential Digital Mammography and MRI for Breast Cancer Screening in High-Risk Patients

Concurrent versus Sequential Digital Mammography and MRI for Breast Cancer Screening in High-Risk Patients Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed (...) Sequential Digital Mammography and MRI for Breast Cancer Screening in High-Risk Patients: Comparative Clinical Effectiveness, Cost- Effectiveness, and Guidelines DATE: 06 May 2015 RESEARCH QUESTIONS 1. What is the comparative clinical effectiveness of concurrent versus sequential digital mammography and magnetic resonance imaging (MRI) for breast cancer screening in high-risk patients? 2. What is the comparative cost-effectiveness of concurrent versus sequential digital mammography and MRI for breast

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Breast Magnetic Resonance Imaging (MRI)

Breast Magnetic Resonance Imaging (MRI) A Applic Date o Context at www 1. An appl treatme of Aust Septem 2. After co and cos plannin ? ? ? ? ? ? MSAC effectiv After co and cos ? Applicatio cant: of MSAC c t for decisio w.msac.gov. Purpose o lication req ent in wome tralia and N mber 2012. MSAC’s a onsidering t st-effectiven ng of newly undergoing with lobula aged 50 yea with very d who have s who have s ductal carci did not sup veness, cost- onsidering t st-effectiven local stagin with metast (...) examinatio Pub on No. 13 onsiderat on: MSAC m au of applica questing Me en newly dia ew Zealand advice to t the availabl ness of MRI diagnosed b g neo-adjuva ar subtype b ars or young dense breast significant s suspicious/m inoma in sit pport public -effectivene the availabl ness of MRI ng and/or ea tatic breast n fails to sh lic Sum 333 – Bre Pro Bre ion: MS makes its ad tion and l dicare Bene agnosed wit d Incorporat the Ministe e evidence p I for local st breast cance ant chemoth breast cancer ger, ts

2015 Medical Services Advisory Committee

17. Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: a meta-analysis

Diagnostic value of MRI combined with ultrasound for lymph node metastasis in breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

18. MRI features predictive of negative surgical margins in patients with HER2 overexpressing breast cancer undergoing breast conservation (PubMed)

MRI features predictive of negative surgical margins in patients with HER2 overexpressing breast cancer undergoing breast conservation Here we develop a tool to predict resectability of HER2+ breast cancer at breast conservation surgery (BCS) utilizing features identified on preoperative breast MRI. We identified patients with HER2+ breast cancer who obtained pre-operative breast MRI and underwent BCS between 2002-2013. From the contoured tumor on pre-operative MRI, shape, histogram, and co (...) -occurrence and size zone matrix texture features were extracted. In univariate analysis, Spearman's correlation coefficient (Rs) was used to assess the correlation between each image feature and an endpoint (surgical re-excision). For multivariate modeling, we employed a support vector machine (SVM) method in a manner of leave-one-out cross-validation (LOOCV). Of 109 patients with HER2+breast cancer who underwent BCS, 39% underwent surgical re-excision. 62% had residual cancer at re-excision

Full Text available with Trip Pro

2018 Scientific reports

19. Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing

Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03475979 Recruitment Status : Recruiting

2018 Clinical Trials

20. Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening

Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>